Impact of Interstitial Lung Abnormalities on Disease Expression and Outcomes in COPD or Emphysema: A Systematic Review

Int J Chron Obstruct Pulmon Dis. 2023 Mar 2:18:189-206. doi: 10.2147/COPD.S392349. eCollection 2023.

Abstract

Background: Both COPD and interstitial lung abnormalities (ILAs) are conditions associated with smoking and age. The impact of coexistent ILAs on the manifestations and outcomes of COPD or emphysema awaits evaluation.

Methods: We searched PubMed and Embase using Medical Subject Headings terms in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Results: Eleven studies were included in the review. The sample size of the studies ranged from 30 to 9579. ILAs were reported in 6.5% to 25.7% of the patients with COPD/emphysema, higher than that reported in the general populations. COPD/emphysema patients with ILAs were older, mostly male, and had a higher smoking index than those without ILAs. Hospital admission and mortality were increased in COPD patients with ILAs compared to those without ILAs, whereas the frequency of COPD exacerbations was discrepant in 2 of the studies. The FEV1 and FEV1% predicted tended to be higher in the group with ILAs, but not significantly in most of the studies.

Conclusion: ILAs were more frequent in subjects with COPD/emphysema than in the general population. ILAs may have a negative impact on hospital admission and mortality of COPD/emphysema. The impact of ILAs on lung functions and exacerbations of COPD/emphysema was discrepant in these studies. Further prospective studies are warranted to provide high-quality evidence of the association and interaction between COPD/emphysema and ILAs.

Keywords: COPD; emphysema; interstitial lung abnormalities; review.

Publication types

  • Systematic Review

MeSH terms

  • Emphysema*
  • Female
  • Humans
  • Lung
  • Male
  • Pulmonary Disease, Chronic Obstructive* / epidemiology
  • Pulmonary Emphysema* / complications
  • Pulmonary Emphysema* / diagnosis
  • Smoking

Grants and funding

YC.S. is supported by the National Natural Science Foundation of China (81970041, 82170048).